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ABSTRACT
Efflux pump inhibitors are of great interest since their use as adjuvants of bacterial
chemotherapy can increase the intracellular concentrations of the antibiotics and
assist in the battle against the rising of antibiotic-resistant bacteria. In this work,
we have described the mode of action of the 2-phenylquinoline efflux inhibitor
(4-(2-(piperazin-1-yl)ethoxy)-2-(4-propoxyphenyl) quinolone – PQQ4R), against
Escherichia coli, by studding its efflux inhibitory ability, its synergistic activity in
combination with antibiotics, and compared its effects with the inhibitors phenyl-
arginine-β-naphthylamide (PAβN) and chlorpromazine (CPZ). The results showed
that PQQ4R acts synergistically, in a concentration dependent manner, with antibiotics
known to be subject to efflux in E. coli reducing their MIC in correlation with the
inhibition of their efflux. Real-time fluorometry assays demonstrated that PQQ4R
at sub-inhibitory concentrations promote the intracellular accumulation of ethidium
bromide inhibiting its efflux similarly to PAβNorCPZ,well-known anddescribed efflux
pump inhibitors for Gram-negative bacteria and whose clinical usage is limited by their
levels of toxicity at clinical and bacteriological effective concentrations. The time-kill
studies showed that PQQ4R, at bactericidal concentrations, has a rapid antimicrobial
activity associated with a fast decrease of the intracellular ATP levels. The results also
indicated that the mode of action of PQQ4R involves the destabilization of the E.
coli inner membrane potential and ATP production impairment, ultimately leading to
efflux pump inhibition by interference with the energy required by the efflux systems.
At bactericidal concentrations, membrane permeabilization increases and finally ATP
is totally depleted leading to cell death. Since drug resistance mediated by the activity
of efflux pumps depends largely on the proton motive force (PMF), dissipaters of PMF
such as PQQ4R, can be regarded as future adjuvants of conventional therapy against
E. coli and other Gram-negative bacteria, especially their multidrug resistant forms.
Their major limitation is the high toxicity for human cells at the concentrations needed
to be effective against bacteria. Their future molecular optimization to improve the
efflux inhibitory properties and reduce relative toxicity will optimize their potential for
clinical usage against multi-drug resistant bacterial infections due to efflux.
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INTRODUCTION
The emergence of drug resistant bacteria represent a global threat to human health and is
now a top priority of the World Health Organization (WHO) and the European Centre for
Disease Prevention and Control (ECDC) programs for the treatment of infectious diseases.
Particularly, the emergence of drug resistance in Escherichia coli requires close attention
since the rate of isolates resistant to the commonly used antibiotics is rising worldwide
(World Health Organization, 2014; European Centre for Disease Prevention and Control,
2015). The current therapeutic options are scarce to deal with these infections. Therefore,
studies on new drugs and drug combinations as well as an improved understanding of
the mechanism of action of these new drugs have become critical to fight the spread of
multidrug resistant organisms.
In Gram-negative bacteria, besides the acquired resistance by the acquisition of external
resistance determinants or mutations in genes that code for the drug targets, the intrinsic
drug resistance also play an important role in the resistance towards antibiotics and biocides
(Viveiros et al., 2007; Piddock, 2006; Piddock, 2007; Nikaido & Pagès, 2012). This resistance
occurs as a consequence of the (i) presence of an outer membrane that create a permeability
barrier reducing the influx of antimicrobials, and (ii) overexpression of efflux pumps that
help to reduce the intracellular level of antimicrobials and toxins (Nikaido & Pagès, 2012;
Piddock, 2006).
The efflux pumps of the RND (resistant nodulation cell division) superfamily have
been clearly associated with multidrug resistant phenotypes in Gram-negative pathogens
(Nikaido & Pagès, 2012). The substrates of the RND efflux pumps are different in their
structure and physicochemical properties and include antibiotics, detergents, and biocides
(Piddock, 2006; Li & Nikaido, 2009). The clinical implication of this substrate promiscuity
is the development of multidrug resistance. The major RND efflux system of E. coli consists
in a typical tripartite efflux pump, the AcrAB-TolC. This structure is composed by an
integral membrane efflux transporter (AcrB), an outer membrane channel (TolC), and
a periplasmic adapter protein (AcrA) (Du et al., 2014). Upon entering in the cell, the
compounds will interact with the substrate-binding pocket of AcrB, which will extrude
the compounds via TolC using the energy produced by the proton motive force (PMF)
(Nikaido & Takatsuka, 2009). The AcrAB activity and overexpression have been associated
with the resistance to fluoroquinolones, chloramphenicol, tetracycline, β-lactams, and
β-lactamase inhibitors, among others, as well as biofilm formation and pathogenicity
(Piddock, 2007). Beside the AcrAB-TolC efflux pump, other E. coli efflux systems also play
a role in the development of drug resistance (Viveiros et al., 2007; Nishino et al., 2003). The
overexpression of these efflux systems in response to the antibiotic stress is commonly the
first step in the evolution of antibiotic resistance in the bacterial population, favoring the
spontaneous appearance and stabilization of chromosomal mutations in the genes related
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with the antibiotic action. This biological phenomenon leads to the emergence of resistance
to almost all classes of antibiotics available and require the urgent implementation of novel
therapeutic strategies for the management of these infections.
The inhibition of the efflux activity may be of great potential once used in combination
therapies by restoring or enhancing the activity of the currently used antimicrobials and
preventing the emergence of drug resistance. Several compounds capable of inhibiting
E. coli efflux pumps have been described (Lomovskaya et al., 2001; Viveiros et al., 2005;
Bohnert, Schuster & Kern, 2013; Opperman et al., 2014; Vargiu et al., 2014; Yilmaz et al.,
2015; Bohnert et al., 2016; Zuo, Weng & Wang, 2016) but, to date, none has reached the
clinical development mainly due to their toxicity. Moreover, the putative mechanisms
of action of the great majority of the efflux inhibitors currently in study remain largely
unknown. The most known E. coli efflux inhibitors are the peptidomimetic phenyl-
arginine- β-naphthylamide (PAβN) and the phenothiazine chlorpromazine (CPZ). PAβN
is a potent inhibitor of Pseudomonas aeruginosa efflux pumps (Lomovskaya et al., 2001)
and is a substrate competitor of the AcrAB efflux pump of E. coli (Viveiros et al., 2008).
Recently,Misra et al. (2015) showed that PAβN acts as an inhibitor of the AcrAB and AcrEF
efflux systems at low concentrations, and as a membrane-destabilizing agent when used at
higher concentrations. The phenothiazine CPZ presents efflux inhibitory activity against
E. coli efflux systems (Viveiros et al., 2005). The phenothiazines mode of action involve
the disruption of the calcium-calmodulin transport and signaling pathways (Salih et al.,
1991; Pluta, Morak-Młodawska & Jeleń, 2011), modifications at the level of the bacterial
membrane and on nucleic acid stability (Pluta, Morak-Młodawska & Jeleń, 2011; Thorsing
et al., 2013), and inhibition of the type II NADH-ubiquinone dehydrogenase (Weinstein et
al., 2005; Schurig-Briccio et al., 2014).
In recent studies, the 2-phenylquinoline derivative PQQ4R showed to be active as
an efflux pump inhibitor of the Gram-positive Staphylococcus aureus (Sabatini et al., 2011;
Sabatini et al., 2013) and non-tuberculousmycobacteria (Machado et al., 2015) but nothing
is known about its mode of action. In this work, we aimed to unravel the mode of action
of PQQ4R as efflux pump inhibitor, as in the search for new and effective efflux inhibitors
is important to understand their inhibitory mechanism of action and to disclosure the
presence of non-efflux related mechanisms (Venter et al., 2015). Because drug efflux is
energy dependent, we hypothesize that the mode by which PQQ4R inhibits drug efflux
involves the interference with the cell energetic state. We evaluated the activity of PQQ4R
using three E. coli isogenic strains differing only in the level of expression of its major
efflux pump system— the AcrAB-TolC system - and compared its activity with that of
the known E. coli efflux inhibitors PAβN and CPZ. We found that PQQ4R interferes with
E. coli membrane integrity, therefore reducing the activity of E. coli efflux pumps. The
understanding gathered on the molecular mechanism of action of the efflux inhibitor
PQQ4R may aid in the development of less toxic and more potent efflux inhibitors against
E. coli efflux pumps.
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MATERIALS & METHODS
Bacteria and growth conditions
The strains included in the study were the wild-type E. coli K-12 AG100 (argE3 thi-1 rpsL
xyl mtl1 (gal-uvrB)supE44); the AcrAB pump-deficient E. coli AG100A (1acrAB), and the
AcrAB overexpressing E. coli AG100tet. The strain AG100A is a derivative of AG100 and has
the AcrAB system inactivated due to an insertion of the transposon Tn903 (1acrAB::Tn903
Kanr) (George & Levy, 1983; Okusu, Ma & Nikaido, 1996). AG100tet is a derivative of
AG100 obtained by continuous exposure to increasing concentrations of tetracycline
(TET) (Viveiros et al., 2005). The strains were grown in Luria-Bertani (LB) broth at 37 ◦C
with shaking. AG100A was grown in presence kanamycin (KAN) at 100 µg/ml to maintain
the transposon and AG100tet was grown in media supplemented with TET at 8 µg/ml to
maintain the overexpression of efflux pumps.
Chemicals
Ofloxacin (OFX), oxacillin (OXA), KAN, TET, ethidium bromide (EtBr), CPZ,
PAβN, carbonyl cyanide-m-chlorophenylhydrazone (CCCP), glucose, and phosphate-
buffered saline (PBS) were purchased from Sigma-Aldrich (St. Louis, MO, USA). The
2-phenylquinoline PQQ4R was synthesized as previously described (Sabatini et al., 2013).
Antibacterial activity evaluation
The minimum inhibitory concentrations (MICs) were determined using the broth
microdilution method according to the CLSI guidelines (Clinical and Laboratory Standards
Institute, 2014). The synergistic activity between the efflux inhibitors, antibiotics and
EtBr was evaluated by checkerboard assays as previously described (Pillai, Moellering
& Eliopoulos, 2005; Coelho et al., 2015). Two-fold serial dilutions of the compounds were
made to achieve the following concentrations: 320 µM–40 µM. TheMICs were determined
as the lowest concentration at which no visible growth was observed after 18 h of incubation
at 37 ◦C. The assays were performed in triplicate and the MIC value was given as result of
at least two concordant values.
Evaluation of efflux activity by real-time fluorometry
The effect of the inhibitors on EtBr accumulation and efflux was assessed by fluorometry as
previously described (Viveiros et al., 2008; Viveiros et al., 2010). The strains were grown
until an OD600 nm of 0.6 at 37 ◦C with shaking. After, the cells were collected by
centrifugation at 16,060× g for 3 min, washed in PBS and centrifuged again.
For the accumulation assays, the OD600 nm of the cell suspension was adjusted to 0.6
by adding PBS, allowing the assay to run with a final OD of 0.3. To determine the EtBr
concentration at which influx and efflux are in equilibrium, the accumulation assays were
performed in presence of increasing concentrations of the dye. The assays were prepared
to a final volume of 100 µl containing 50 µl of the cellular suspension (final OD600 nm of
0.3) plus 50 µl of EtBr solutions to final concentrations ranging from 0.0625 to 5 µg/ml.
The effect of the inhibitors on the accumulation of EtBr was evaluated in a final volume
of 100 µl containing 50 µl of the cellular suspension (final OD600 nm of 0.3) and 50 µl
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Table 1 Minimum inhibitory concentration (MIC) determination of the antibiotics, EtBr and efflux
inhibitors against the E. coli strains.
MIC for the E. coli strains
AG100a AG100Ab AG100tetc
Compound (µg/ml) (µM) (µg/ml) (µM) (µg/ml) (µM)
Antibiotics
OFX 0.25 – 0.0313 – 1 –
TET 2 – 0.5 – 64 –
OXA 512 – 2 – >2,048 –
Efflux inhibitors
PQQ4R 256 653.9 32 81.7 >256 >653.9
CPZ 120 337.8 60 168.9 280 788
PAβN >200 >385 50 96.3 >200 >385
Efflux substrate
EtBr 200 – 3.125 – 512 –
Notes.
aE. coli AG100—wild-type.
bE. coli AG100A—AG100 with the AcrAB-TolC efflux pump inactivated.
cE. coli AG100tet—AG100 with efflux pump overexpression.
CPZ, chlorpromazine; EtBr, ethidium bromide; OFX, ofloxacin; OXA, oxacillin; PAβN, phe-arg- β-naphthylamide; TET,
tetracycline.
of a solution containing EtBr at the equilibrium concentration and the compounds to
a final concentration of 80 µM for AG100 and AG100tet, and 20 µM for AG100A. The
molar concentrations used represent 14 or less of the MIC determined for each compound
against each strain (see Table 1) in order to guarantee that the real-time efflux inhibitory
effects measured were not due to any antimicrobial effect of the compound. The assays
were conducted in a Rotor-Gene 3000 (Corbett Research, Sydney, Australia) at 37 ◦C,
and the fluorescence acquired at 530/585 nm at the end of every 60 s, for 30 min. The
activity of the compounds on the accumulation of EtBr was evaluated by the relative final
fluorescence (RFF) index according to the formula: RFF= (RFtreated–RFuntreated)/RFuntreated.
In this formulae the RFtreated corresponds to the fluorescence at the last time point of the
EtBr accumulation curve (minute 30) in the presence of an inhibitor and the RFuntreated
corresponds to the fluorescence at the last time point of the EtBr accumulation curve of
the control tube (Machado et al., 2011). The experiments were done in triplicate and the
RFF values are presented as the average of three independent assays (±SD).
For the efflux assays, the strains were exposed to conditions that promote maximum
accumulation of EtBr, i.e., EtBr at the equilibrium concentration for each strain, no glucose,
presence of the efflux inhibitors, and incubation at room temperature for 1 h (Viveiros
et al., 2010). The OD600 nm of the cell suspension was adjusted to 0.3 and incubated with
EtBr under the conditions described above. Aliquots of 50 µl of the cells were transferred
to tubes containing 50 µl of each efflux inhibitor at 80 µM (AG100 and AG100tet) or 20
µM (AG100A) without EtBr. Control tubes with only cells and cells with and without
0.4% glucose were included. The fluorescence was measured in a Rotor-Gene 3000 and
the data was acquired every 30 s for 30 min at 37 ◦C. The efflux activity was quantified by
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comparing the fluorescence data obtained under conditions that promote efflux (presence
of glucose and absence of efflux inhibitor) with the data from the control in which the
bacteria are under conditions of no efflux (presence of an inhibitor and no energy source).
The relative fluorescence corresponds to the ratio of the fluorescence that remains per unit
of time, relatively to the EtBr-loaded cells (Viveiros et al., 2008; Viveiros et al., 2010).
Time-kill kinetics
The determination of the killing activity of PQQ4R was analysed by time-kill assays
as previously described (Pillai, Moellering & Eliopoulos, 2005) with slight modifications.
Briefly, AG100 was grown until OD600 nm of 0.6 at 37 ◦Cwith shaking. Exponential bacterial
cultures were diluted in Mueller-Hinton Broth (MHB) to a cell density of 1×105 cells/ml
and 500 µl added to test tubes containing MHB and PQQ4R at the desired concentration.
The compoundwas added to each tube to achieve the final concentrations of 8× to 0.5× the
MIC. A drug-free control was included in the assay to monitor the normal growth of the
strain. Cultures were sampled for CFU determination after 0, 1, 2, 3, 4, 5, 6, and 24 h of
incubation at 37 ◦C with shaking. For CFU determination, 10-fold serial dilutions were
made in a saline solution and 20 µl of each solution was placed onto the surface of a
Mueller–Hinton agar plate. The colonies were counted after the incubation of the plates at
37 ◦C for 24 h. The limit of detection of the assay was 17 CFU/ml. Each assay was repeated
at least twice.
Membrane potential assay
The effect of PQQ4R on the membrane potential was measured using the BacLight
Bacterial Membrane Potential Kit (Molecular Probes, Life Technologies) according to
the manufacturer’s instructions. CPZ and PAβN were tested for comparison. AG100
was grown at 37 ◦C with shaking until reach OD600 nm 0.6. After this, the cells were
washed in PBS and diluted to 1×107 CFU/ml with PBS. PQQ4R was added to the cell
suspension at concentrations from 640 to 80 µM. The samples were transferred into black
flat bottom 96-well plates, 30 µM of DiOC2 (3) was added to the mixture, and the plates
were incubated during 30 min in the dark. The fluorescence was measured using a Synergy
HT multi-mode microplate reader (BioTek Instruments Inc, Vermont, USA) with the
filters 485/20 (excitation) and 528/20 (emission) for green and 590/35 (emission) for red.
CCCP was used as positive control at 156 µM (half MIC), since it eradicates the proton
gradient, eliminating the membrane potential. The red to green ratio was determined and
normalized against the emission from theDiOC2 (3) blankwell and the results are presented
as the percentage of depolarized membranes (±SD) compared with the drug-free control.
Membrane permeability assay
The evaluation of the membrane integrity was done using the Live/Dead BacLight Bacterial
Viability Kit (Molecular Probes, Life Technologies) according to the manufacturer’s
instructions. AG100 was grown at 37 ◦C with shaking until OD600 nm of 0.6. Samples of
500 µl were incubated with PQQ4R at concentrations from 640 to 80 µM during 1 h at
room temperature. The cells were collected by centrifugation at 16,060× g for 10 min,
the supernatant was discarded and the pellet resuspended in the same volume of a saline
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solution. Then, 100 µl of the cell suspension were transferred into black flat bottom 96-well
plates and the dyes propidium iodide and SYTO 9 (ratio 1:1) were added to each well to
stain the cells. The plate was incubated during 15 min at room temperature in the dark.
The fluorescence was measured using a Synergy HT multi-mode microplate reader with
the filters 485/20 (excitation) and 528/20 (emission) for green and 590/35 (emission) for
red. The green to red ratio was determined and the results are presented as the percentage
of intact membranes (±SD) compared with the control (no treatment). CPZ and PAβN
were included for comparison.
Intracellular ATP levels determination
The ATP levels were measured using the ATP Determination Kit (Invitrogen, Life
Technologies, Paisley, UK) according to the manufacturer’s instructions. AG100 was
grown until OD600 nm of 0.6 at 37 ◦C with shaking. Exponential bacterial cultures were
diluted inMHB to a cell density of 1×105 cells/ml and 500µl added to test tubes containing
MHB and PQQ4R at half MIC and at the MIC. A drug-free control was included in the
assay to monitor the normal growth of the strain. Aliquots of bacteria were collected at 0,
1, 2, 3, 4, 5, 6, and 24 h of incubation at 37 ◦C, with shaking, inactivated by heating and
immediately deep frozen. The cell lysates were transferred into white flat bottom 96-well
plates and the ATP content measured using a Synergy HT multi-mode microplate reader
and expressed as relative luminescence units. CPZ andPAβNwere included for comparison.
Cytotoxicity against human monocyte-derived macrophages
The blood was collected from healthy donors and the peripheral blood mononuclear cells
were isolated by Ficoll-Paque Plus (GE Healthcare, Freiburg, Germany) density gradient
centrifugation as previously described (Machado et al., 2016). Briefly, monocytes were
differentiated into macrophages during 7 days in RPMI-1640 medium with 10% fetal
calf serum (FCS), 1% GlutaMAXTM, 1 mM sodium pyruvate, 10 mM HEPES at pH 7.4,
100 IU/ml penicillin and 100 µg/ml streptomycin (Gibco, Life Technologies), and 20
ng/ml M-CSF (Immunotools, Friesoythe, Germany) and incubated at 37 ◦C in a 5% CO2
atmosphere. Fresh medium was added at day 4 post isolation. The effect of the compounds
on human monocyte-derived macrophages was evaluated using the AlamarBlue method
(Molecular Probes, Life Technologies) (O’Brien et al., 2000), and by measuring the release
of the lactate dehydrogenase (LDH) into the culture supernatants using the Pierce LDH
Cytotoxicity Assay (ThermoFisher Scientific, Waltham, MA, USA) (Chan, Moriwaki &
Rosa, 2013) according to the manufacturer’s instructions. Briefly, 5×104 cells were seeded
in 96-well microplates treated with the compounds, and incubated at 37 ◦C with 5% CO2.
After 72 h of treatment, the cell viability was assessed. For the AlamarBlue method, the dye
was added to each well to a final concentration of 10% and incubated overnight at 37 ◦C
and 5% CO2. The fluorescence was measured with a 540/35 excitation filter and a 590/20
emission filter in a Synergy HT multi-mode microplate reader. The release of LDH from
damaged cells into culture supernatants, as an indicator of cytotoxicity, was measured
in serum-free medium. Here the amount of enzyme activity correlates to the number of
damaged cells. The specific lysis was calculated as follows: (treated cells—spontaneous
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LDH release)/ (maximum LDH release—spontaneous LDH release) ×100. The inhibitory
concentration IC50 (50%) value was calculated using GraphPad Prism V5.01 software (La
Jolla, USA). The IC10 (10%) and IC90 (90%) were calculated using the GraphPad program
‘‘ECanything’’ available online (Graph Pad Software, 2016).
Statistical analysis
Statistical analysis was carried out using the Student’s t -test. A P value <0.05 was considered
statistically significant and highly significant when ∗∗P < 0.01 and ∗∗∗P < 0.001 (two-tailed
tested).
RESULTS
Synergistic activity of PQQ4R in combination with antimicrobials
The MICs of the antibiotics, which are substrates of the AcrAB efflux pump, the efflux
substrate EtBr, PQQ4R, and for comparison, PAβN and CPZ, known E. coli efflux
inhibitors, were determined for the wild-type AG100, the pump deficient AG100A,
and the pump-overexpressing AG100tet (Table 1). AG100A is more susceptible to the
selected antibiotics and EtBr than the wild-type, due to the absence of a functional AcrAB,
reconfirming that these antibiotics are substrates of this pump (Piddock, 2006; Viveiros et
al., 2005). The susceptibility data also showed that neither PQQ4R nor PAβN and CPZ
had, by themselves, antimicrobial activity against the E. coli strains. Moreover, PQQ4R
MIC decreased 8-fold against AG100A once compared with the wild-type parental strain,
indicating that, PQQ4R might be a substrate of the AcrAB system. Similar results were
observed for PAβN.
To assess whether PQQ4R potentiated the activity of the tested antibiotics against
E. coli, the MICs of OFX, OXA, and TET were determined in the presence of PQQ4R.
PAβN and CPZ were tested at the same concentrations for a direct comparison of their
activities (Table 2). Against the wild-type strain, PQQ4R, at concentrations ranging from
40 to 160 µM, produced a 2-fold reduction in OFX and TET MICs, while a 2- or 4-fold
reduction on the MICs of EtBr at 80 and 160 µM, respectively, were observed. On the
contrary, no effect was observed for OXA. Interestingly, PQQ4R at concentrations of
80 and 160 µM, significantly increased the antibacterial activity of OFX and TET in the
AcrAB-overexpressing strain AG100tet, (AcrAB overexpressed 6–10 times compared with
the isogenic wild-type strain—Viveiros et al., 2005; Viveiros et al., 2007) causing a 4-fold
decrease in their MICs, with a marginal effect on the MIC of EtBr. In accordance with
the increased susceptibility detected above, the pump deficient AG100A did not grow in
presence of PQQ4R at concentrations above 40 µM and this concentration had no effect
on the MIC of the antibiotics. However, this concentration caused a ≈8-fold reduction in
the EtBr MIC for AG100A, confirming that other efflux pumps, that extrude EtBr (AcrEF,
among others), are active in this strain (Viveiros et al., 2005; Viveiros et al., 2007).
The presence of PAβN significantly reduced the MICs of OXA and TET on the three
strains. PAβN reduced the MIC of TET and OXA on the pump-deficient strain by 16-fold
and 4-fold, respectively; however, it showed no effect on OFX and EtBr MICs. Conversely,
the exposure to PAβN produced a 128-fold decreased in the MIC of EtBr against the
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Table 2 Synergistic effect of PQQ4R, PAβN, and CPZ on theMIC values of antibiotics and EtBr against the E. coli strains.
MIC (µg/ml)
OFX OXA TET EtBr
Strain [PQQ4R] (µM) [PQQ4R] (µM) [PQQ4R] (µM) [PQQ4R] (µM)
0 40 80 160 0 40 80 160 0 40 80 160 0 40 80 160
AG100 0.25 0.125 0.125 0.125 512 512 512 512 2 1 1 1 200 200 100 50
AG100A 0.03 0.03 – – 2 1 – – 0.5 0.25 – – 3.125 0.39 – –
AG100 tet 1 0.5 0.25 0.25 >2,048 >2,048 2,048 2,048 64 16 16 16 512 512 512 512
[PAβN] (µM) [PAβN] (µM) [PAβN] (µM) [PAβN] (µM)
0 40 80 160 0 40 80 160 0 40 80 160 0 40 80 160
AG100 0.25 0.06 0.06 0.06 512 64 64 64 2 2 1 0.06 200 100 100 100
AG100A 0.03 0.03 – – 2 0.25 – – 0.5 0.03 – – 3.125 3.125 – –
AG100tet 1 0.06 0.03 0.03 >2,048 256 256 64 64 8 4 2 512 256 128 4
[CPZ] (µM) [CPZ] (µM) [CPZ] (µM) [CPZ] (µM)
0 40 80 160 0 40 80 160 0 40 80 160 0 40 80 160
AG100 0.25 0.125 0.125 0.003 512 512 512 ≤1 2 1 0.5 ≤0.03 200 100 25 ≤0.39
AG100A 0.03 0.015 – – 2 2 – – 0.5 0.125 – – 3.125 0.39 – –
AG100 tet 1 0.5 0.5 0.25 >2,048 >2,048 2,048 1,024 64 32 32 16 512 256 128 128
Notes.
aE. coli AG100—wild-type.
bE. coli AG100A—AG100 with the AcrAB-TolC efflux pump inactivated.
cE. coli AG100tet—AG100 with efflux pump overexpression








Table 3 Relative final fluorescence values (RFF) based on the accumulation of EtBr for the E. coli strains in the presence of the efflux inhibitors.
AG100a AG100Ab AG100tetc
Compound (80 µM) RFF Compound (20 µM) RFF Compound (80 µM) RFF
PQQ4R 13.1± 0.04*** PQQ4R 1.5± 0.1** PQQ4R 5.2±0.9***
CPZ 8.1± 1.1*** CPZ 2.0± 0.04** CPZ 7.9±0.4***
PAβN 0.7± 1.2* PAβN 0.1± 0.1 PAβN 1.3± 0.3**
Notes.
aE. coli AG100—wild-type.
bE. coli AG100A—AG100 with the AcrAB-TolC efflux pump inactivated.
cE. coli AG100tet—AG100 with efflux pump overexpression.
CPZ, chlorpromazine; EtBr, ethidium bromide; PAβN, phe-arg- β-naphthylamide; Accumulation of EtBr at 1 µg/ml (AG100), 0.25 µg/ml (AG100A) and 2 µg/ml (AG100tet) in
the absence of glucose; Values in bold type (RFF ≥1) indicated enhanced accumulation of EtBr in presence of an efflux inhibitor. The results presented correspond to the average
of three independent assays plus standard deviation (±SD). Results were considered significant when *P < 0.05 and highly significant when **P < 0.01 and ***P < 0.001; CPZ,
chlorpromazine; PAβN, phe-arg- β-naphthylamide, EtBr, ethidium bromide.
AcrAB-overexpressing strain, while no change was observed in the MIC of the wild-type
strain. The inability of PAβN to reduce the MIC of EtBr in wild-type strains has already
been described for E. coli and P. aeruginosa (Lomovskaya et al., 2001; Kern et al., 2006). This
result indicates that PAβN is acting as a pump competitor and not as an efflux inhibitor
like PQQ4R and CPZ. The activity of CPZ against the pump-deficient strain was similar
to that of PQQ4R, with the exception that CPZ reduced the MIC of TET by 4-fold. CPZ
significantly reduced the MICs of OFX, OXA, TET and EtBr on the wild-type and the
AcrAB-overexpressing strain.
Efflux inhibitory activity of PQQ4R
The MIC results give an indirect measure of the potential efflux activity of the strains and
the effect of the inhibitors on this activity. The ability of PQQ4R to inhibit E. coli efflux
systems was confirmed by real-time fluorometry using EtBr, a broad efflux pump substrate
(Viveiros et al., 2008; Viveiros et al., 2010). Initially, it was determined the equilibrium
concentration at which the influx of EtBr equals its efflux. The accumulation of EtBr
started at concentrations above 1 µg/ml for AG100, 0.25 µg/ml for AG100A, and 2 µg/ml
for AG100tet (Fig. S1). Using these concentrations, we evaluated the ability of PQQ4R,
at sub-inhibitory concentrations (<1/8 MIC), to promote the intracellular accumulation
of EtBr (Fig. 1) and calculated the RFFs (Table 3). The RFF value is a measure of how
effective the compound is on the inhibition of the EtBr efflux (at a given concentration)
by comparison of the final fluorescence at the last time point (60 min) of the treated cells
with the cells treated only with EtBr. An index of activity above zero indicated that the cells
accumulate more EtBr under the condition used than those of the control (non-treated
cells taken as 0). In case of negative RFF values, these indicated that the treated cells
accumulated less EtBr than those of the control condition. Values above 1 in the presence
of the efflux inhibitors were considered enhanced accumulation of EtBr inside the cells.
CPZ and PAβN were included at the same concentrations for a direct comparison of their
inhibitory potencies.
At 80µM, PQQ4R showed an RFF of 13.1 against the wild-type strain, indicating a strong
ability to interfere with EtBr efflux compared to CPZ and PAβN, that showed RFF values
of 8.1 and 0.7, respectively (Fig. 1A; Table 3). This means that PQQ4R promotes the higher
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Figure 1 Effect of PQQ4R, CPZ, and PAβN on the accumulation of ethidium bromide by E. coli. (A)
AG100; (B) AG100A; and (C) AG100tet. The equilibrium concentration of ethidium bromide was 1 µg/ml
for AG100, 0.25 µg/ml for AG100A, and 2 µg/ml for AG100tet. Assays were performed at 37 ◦C in the ab-
sence of glucose. The inhibitors were used at 80 µM for AG100 and AG100tet, and 20 µM for AG100A.
EtBr, ethidium bromide; CPZ, chlorpromazine; PAβN, phenyl-arginine- β-naphthylamide.
accumulation levels of EtBr compared to CPZ followed by PAβN. In the AcrAB-deficient
strain there was a small increase in the accumulation of EtBr in the presence of PQQ4R
(RFF = 1.5) and CPZ (RFF = 2), whereas almost no effect was observed with PAβN (RFF
= 0.1) (Fig. 1B; Table 3). These results showed once again that AcrAB is the main efflux
system that pumps out EtBr in E. coli, but that other efflux pumps susceptible to PQQ4R
and CPZ are pumping out EtBr as described before (Viveiros et al., 2005; Viveiros et al.,
2007). For the AcrAB-overexpressing strain AG100tet (AcrAB is 6–10 times overexpressed
compared to the wild-type strain), the accumulation of EtBr in the presence of PQQ4R
corresponded to a RFF of 5.2 (Fig. 1C; Table 3). The EtBr accumulation in this strain
increased significantly when compared to AG100A, but, for the same molar concentration
of inhibitor tested (80 µM), did not reach the same levels of inhibition observed for AG100,
since the AcrAB system is 6–10 times more expressed in the AG100tet strain compared
with the AG100 (Viveiros et al., 2008; Viveiros et al., 2010). These results, obtained in a set
of three isogenic E. coli that differ only by the absence/presence or expression level of the
AcrAB system, indicated that PQQ4R promotes accumulation (i.e., interferes with the
efflux) of EtBr in E. coli mainly thought the inhibition of the AcrAB efflux system. In the
presence of CPZ and PAβN, the EtBr accumulation in the AG100tet reaches similar levels
(RFF 7.9 and 1.3, respectively) to those obtained for the wild-type strain (RFF 8.1 and 0.7,
respectively), being less effective in the inhibition of efflux activity than PQQ4R.
To confirm the results obtained above on the accumulation of EtBr promoted by the
inhibitors, we performed efflux assays for each strain. Each strain was subject to conditions
that promote significant EtBr accumulation over a period of 60 min at room temperature:
in the absence of glucose and presence of PQQ4R, CPZ or PAβN. After the maximum
accumulation has been reached, EtBr and the efflux inhibitors were washed-out and the
cells were subsequently re-suspended in new buffer with and without glucose and the
inhibitor. As showed in Fig. 2, the efflux take place readily in presence of glucose at 37 ◦C,
an activity that is inhibited in the presence of PQQ4R and CPZ and to a lesser extent with
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Figure 2 Effect of PQQ4R, CPZ, and PAβN on the efflux of EtBr by the E. coli strains. (A) AG100;
(B) AG100A; and (C) AG100tet. The assays were performed at 37 ◦C in the presence and absence of glu-
cose. The concentrations of PQQ4R, CPZ and PAβN were 80 µM for AG100 and AG100tet, and 20 µM for
AG100A. EtBr, ethidium bromide; CPZ, chlorpromazine; PAβN, phenyl-arginine-β-naphthylamide.
PAβN. These results confirmed that PQQ4R, CPZ, and PAβN inhibit the efflux of EtBr
and this inhibitory effect is transient when the cells are washed-out of the inhibitor and an
energy source is given to promote active efflux reenergizing the cells (Fig. 2).
Membrane depolarization and cell viability
To test the hypothesis that the interference with the bacterial energy metabolism is the
cause of the efflux inhibition by PQQ4R, the effect of this compound on the bacterial
membrane potential was evaluated using the BacLight Bacterial Membrane Potential
Kit. Thirteen minutes after adding PQQ4R at any of the concentrations tested, the
percentage of depolarized cells was over 85% (Fig. 3A). The protonophore CCCP was used
as depolarization control and, as expected, themembrane potential collapsed when the cells
were incubated for the same timewith CCCP (over 95%). These results showed that PQQ4R
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Figure 3 Membrane depolarization (A) and permeabilization (B). The relative red/green ratio of
E. coli using DIOC2 (3) stained cells after 30 min of exposure to PQQ4R from 80 µM to 640 µM. Green
fluorescence corresponds to the depolarized cells; red fluorescence corresponds to the polarized cells.
The changes in the fluorescence were measured at an excitation wavelength of 485/20 nm and 528/20
(emission) for green and 590/35 (emission) for red; (B) Membrane permeability measured with Baclight
Live/Dead assay upon exposure to PQQ4R. Green fluorescence corresponds to the cells with intact
membranes; red fluorescence corresponds to cells with permeabilized membranes cells. The data was
normalized against the drug-free control. CCCP was used as positive control, at 156 µM (half MIC), since
it eradicates the proton gradient, eliminating membrane potential. The results presented correspond to
the average of two independent assays plus standard deviation (±SD). Results were considered significant
when ∗P < 0.05 and highly significant when ∗∗P < 0.01 and ∗∗∗P < 0.001.
depolarizes E. coli membranes by interfering with the gradient of protons through the cell
membrane. Then, to evaluate if the depolarization of the cells, promoted by PQQ4R, results
on a transient effect on cells with an intact membrane or alters the membrane integrity,
the Live/Dead BacLight Bacterial Viability Kit was used. This assay uses the fluorescent
stain SYTO 9 that penetrates in all bacterial membranes and stains the cells in green,
and propidium iodide that penetrates only in the cells with permeabilized membranes.
The combination of the two stains produces red fluorescent cells and these latter ones
are considered dead by cell damage. The integrity of E. coli membranes was evaluated, by
fluorometry, after exposure to PQQ4R at sub-inhibitory (1/4 and 1/2MIC) and bactericidal
concentrations (MIC), during 1 h. The results showed that at half MIC, PQQ4R caused
cell damage, reducing the membrane integrity by 28% (Fig. 3B). This increased membrane
permeability was accompanied by a reduction in the bacterial viability of approx. 1 log
(Fig. 4—see also kinetics of bacterial killing). Membrane integrity was then evaluated on
the cells exposed to PQQ4R at 80 µM (≈1/8 MIC), the same concentration used in the
real-time fluorometry accumulation and efflux assays, for 1 h and the results were assessed
as described before. At 80 µM, PQQ4R did not alter the cell membrane integrity (Fig. 3B).
To evaluate if the EtBr accumulation observed in presence of CPZ and PAβN was due to
membrane permeability we tested both compounds also at 80 µM. The results showed that
the membrane permeability increased by 18% and 14% with CPZ and PAβN, respectively.
Membrane depolarization occurs in presence of CPZ at 80 µM similarly to that caused
by PQQ4R, and PAβN induced 14% membrane depolarization at 80 µM. Overall, these
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Figure 4 Effect for PQQ4R on survival of E. coli. AG100. The compound was added at concentrations
from 0.5×MIC (320 µM) to 8×MIC (5,120 µM) to exponential growing E. coli and survival monitored
during 24 h.
results showed that PQQ4R causes transient membrane depolarization without affecting
membrane integrity or cell viability at low concentrations (80 µM - 1/8 MIC- cell viability
at this concentration 14.34 log10 CFU/ml—Fig. 4). In contrast, and as expected by the
previous results, at bactericidal concentrations, PQQ4R acts as a membrane-destabilizing
agent, which is also consistent with the cell death at this concentration (Fig. 4). The
gathering of these results points towards the depolarization of the cell membrane as the
main mechanism for PQQ4R’s transient efflux-inhibition activity.
PQQ4R effect on intracellular ATP levels
Destabilization of the membrane functions can impair the respiratory chain functions and
consequently reduce the ATP levels. To evaluate whether the exposure to PQQ4R could
have an effect on the intracellular ATP levels, E. coli AG100 was exposed to PQQ4R and
the intracellular ATP levels measured during 24 h at either sub-inhibitory (320 µM –1/2
MIC) or bactericidal concentrations (640 µM—MIC) (Fig. 5). The ATP levels remained
constant during the first 3 h of exposure at both concentrations and at the same level of
the drug-free control excluding the abrupt ATP depletion from being the direct cause of
the efflux-inhibition previously seen with the EtBr accumulation and efflux assays, and
supports a slow but steady ATP production impairment. After 4 h of exposure, the ATP
levels of the drug-free control increased but the ATP levels of the drug-containing tubes
remained practically constant after the addition of PQQ4R and until the end of the assay,
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Figure 5 Effect of PQQ4R on E. coli ATP levels. E. coli AG100 was exposed to PQQ4R at half MIC and
MIC/MCB during 24 h. The ATP levels were quantified using a luciferin-luciferase bioluminescence detec-
tion assay as described in ‘Material and Methods’. The results presented correspond to the average of two
independent assays plus standard deviation (±SD). Results were considered significant when ∗P < 0.05
and highly significant when ∗∗P < 0.01 and ∗∗∗P < 0.001.
with the exception of the cells exposed to half MIC. In this case, the ATP production
increased after 24 h of exposure but was 80% less than that of the drug-free control.
Kinetics of PQQ4R bacterial killing
To characterize the killing effect of PQQ4R, wemeasured its bacterial killing activity against
AG100 through time-kill studies (Fig. 4). PQQ4R at half MIC had no effect on the viability
of E. coli after 24 h of exposure. Exposure to PQQ4R reduced the viability of E. coli to zero
after 3 h at the MIC (256 µg/ml–640 µM) while at 2×MIC PQQ4R reduced the viability
to zero after 1 h of exposure. After 24 h of exposure, all cultures remained negative at
these concentrations. These results showed that PQQ4R killing activity is rapid reaching
100% lethality at the MIC, a concentration that was also found to be bactericidal (minimal
bactericidal concentration—MBC).
Spectrum of activity of PQQ4R
The antimicrobial activity of PQQ4R was evaluated against other bacterial species to
assess its antibacterial specificity: the Gram-negative bacteria Acinetobacter baumannii,
Salmonella enterica serovar Enteritidis, Klebsiella pneumoniae and Enterobacter aerogenes,
the Gram-positive S. aureus, and the acid-fast bacteria Mycobacterium smegmatis, M.
avium, and M. tuberculosis. The results are depicted in Table 4 and showed that PQQ4R
possessed moderate antibacterial activity towards Gram-positive (average MIC 50 µg/ml)
and acid-fast bacteria (average MIC 32 µg/ml) and reduced antibacterial activity against
Gram-negative bacteria (average MIC ≥ 128 µg/ml).
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Table 4 Antibacterial specificity of PQQ4R against a panel of selected bacterial species.
Species Strain MIC (µg/ml)
PQQ4R
Enterobacter aerogenes ATCC13048 >256
Salmonella enterica serovar Enteritidis NCTC13349 256
Escherichia coli K-12 AG100 256
Acinetobacter baumannii ATCC19606T 128
Klebsiella pneumoniae FF4891 >256
Staphylococcus aureus ATCC25923 50
Mycobacterium smegmatismc2155 ATCC700084T 32
Mycobacterium avium 104 32
Mycobacterium tuberculosisH37Rv ATCC27294T 32
Table 5 Cytotoxic concentrations (CC) of PQQ4R, PAβN, and CPZ against humanmonocyte-derived
macrophages after three days of exposure.
Cytotoxic concentrations (µM)
Compound CC90 CC50 CC10
PQQ4R 12.73 10.83 9.21
CPZ 37.01 22.24 13.36
PAβN 3596.86 1269 447.71
Notes.
CPZ, chlorpromazine; PAβN, phe-arg-β-naphthylamide.
Cytotoxicity
Finally, PQQ4R was evaluated for its toxicity against human monocyte-derived
macrophages using CPZ and PAβN for comparison. After 72 h of exposure, the viability of
the macrophages was assessed using the AlamarBlue method. The comparative activities,
CC90, CC50 and CC10 values, are presented in Table 5. The dose–response curves are
shown in Fig. 6. PQQ4R showed to be more toxic (CC50 10.83 µM) when compared
to CPZ (CC50 22.24 µM) and PAβN (CC501269 µM). Afterwards, the amount of LDH
release was measured in the cultures supernatants (Fig. 7). The LDH is an intracellular
enzyme that is released in the culture media as a consequence of damaged cell membranes
(Chan, Moriwaki & Rosa, 2013). The treatment with PQQ4R at 0.625 µM–2.5 µM caused
1%–4.6% increase in LDH release compared with the non-treated cells; at 5 µM LDH
release increases by 52.45% and to 72%–78% at higher concentrations. Comparatively,
CPZ increases LDH release from 0.95% at 1.25 µM to 24% at 20 µM. At concentrations
above, the amount of LDH detected in the culture supernatant was above 95%. Concerning
PAβN, the amount of LDH detected varied from 1.08% to 8% at concentrations from 10
µM to 640 µM. At concentrations above, PAβN caused 66%–68% LDH release. The results
obtained with the LDH method corroborated the results obtained with the AlamarBlue
method.
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Figure 6 Dose response curves showing the effect of PQQ4R, CPZ and PAβN against human-
monocyte derived macrophages. The cells were treated with different concentrations of (A) PQQ4R, (B)
CPZ, and (C) PAβN for 3 days; AlamarBlue was then added and cells were further incubated overnight
at 37 ◦C, 5% CO2. The fluorescence was measured Synergy HT multi-mode microplate reader. CPZ,
chlorpromazine; PAβN, phenyl-arginine-β-naphthylamide.
Figure 7 Effect of PQQ4R, CPZ and PAβN on LDH release from humanmonocyte-derived
macrophages. The cells were exposed to each compound during 3 days at 37 ◦C, 5% CO2. The
results presented correspond to the average of at least two independent assays plus standard deviation
(±SD). Results were considered significant when ∗P < 0.05 and highly significant when ∗∗P < 0.01 and
∗∗∗P < 0.001.
DISCUSSION
To detail the biological activity on the 2-phenylquinoline efflux inhibitor PQQ4R against E.
coli, we investigated first the synergistic activity of PQQ4R in combination with antibiotics
that are known substrates of the AcrAB efflux pump. The results showed that PQQ4R
acts synergistically, in a concentration dependent manner, with the antibiotics TET and
OFX. When compared to CPZ and PAβN, PQQ4R is less potent in its synergistic activity
at equivalent molarities. Next, we explored the effect of PQQ4R on the real-time active
efflux of the AcrAB efflux substrate EtBr. PQQ4R, CPZ, and PAβN clearly inhibited the
efflux of EtBr in a transient manner at sub-inhibitory concentrations (1/8 MIC or less), as
shown by the reactivation of active efflux when the cells are released from the inhibitor and
reenergized by glucose. As expected, the re-energization effect was more significant with
CPZ (known to inhibit AcrAB-mediated EtBr efflux by energy depletion) (Viveiros et al.,
2005) compared with PAβN, an AcrAB substrate competitor partially affecting membrane
integrity (Misra et al., 2015). PQQ4R clearly demonstrated a real-time inhibitory effect on
efflux similar to CPZ.
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In terms of antimicrobial properties, PQQ4R demonstrated a rapid bactericidal activity
against E. coli with the complete loss of viable cells after only 1 h incubation at 2× MIC
and after 4 h at its MIC. This result is consistent with our hypothesis of an alternative
mode of action in which at low concentrations PQQ4R inhibit E. coli efflux systems and
near the MBC it interact directly with E. colimembranes. Our results showed that PQQ4R
mechanism of action involves the loss of membrane integrity after 1 h of exposure. PQQ4R
disrupts both inner and outer membrane, as the uptake of the membrane-impermeant
fluorescent dye propidium iodide requires the damage of both to enter in the cytoplasm,
to bind to the DNA and fluoresce. Recently, it was showed that PAβN also permeabilizes
the E. coli outer membrane (Misra et al., 2015) and both outer and inner membranes of
P. aeruginosa (Lamers, Cavallari & Burrows, 2013).
The loss of the membrane integrity is closely related with the loss of the cell capacity
to synthesize ATP, decreased protein synthesis and to inhibit respiration (Brogden, 2005).
Our data showed a moderate increase in the ATP levels after the addition of PQQ4R at
sub-inhibitory concentrations (half MIC), associated with a decrease in the membrane
permeability. At bactericidal concentrations (MIC), the ATP levels decreased and were
accompanied by an increase in the membrane permeability. To further support these
results, and based upon the fact that the RND efflux pumps act using the electrochemical
gradient generated by the PMF (Anes et al., 2015), we assessed whether treatment with
PQQ4R could have a direct effect on membrane depolarization. Our results showed
that PQQ4R causes a significant, but non-lethal, inner membrane depolarization at sub-
inhibitory concentrations. At bactericidal concentrations, the membrane depolarization is
accompanied by an impaired membrane integrity and ATP production, with cell death.
The sequence of events describing PQQ4R mechanism of action is depicted in Fig. 8.
Briefly, PQQ4R at low concentrations inhibit E. coli efflux systems by interfering with the
energy necessary to maintain the pumps working, i.e., PQQ4R is an energetic inhibitor
like CPZ and inhibits the efflux activity through the transient dissipation of the membrane
potential without affecting the membrane permeability. Also similar to CPZ and PAβN,
at higher concentrations PQQ4R permeabilizes E. coli membranes causing irreversible cell
damage leading to the cell death. Of note, despite several attempts, we could not obtain
E. coli mutants to PQQ4R. This result showed that PQQ4R has an off-target effect and
corroborates our findings that points to membrane disruption as the primary mechanism
of action of this molecule.
Regrettably, PQQ4R revealed to be relatively toxic to the human macrophage, with a
toxicity level comparable to that of CPZ, an antipsychotic already used in clinical practice
and previously shown to have activity against intracellular M. tuberculosis at non-toxic
clinical concentrations due to its accumulation inside the phagolysosomal macrophage
compartments (Machado et al., 2016). In a recent study, we showed that PQQ4R, when
used at non-toxic concentrations, is also able to potentiate clarithromycin activity against
intracellularM. avium in a manner similar to CPZ (Machado et al., 2015). On the contrary,
PAβN showed almost no toxicity against the human macrophages, however, PAβN and
its derivatives proved to be nephrotoxic as result of their accumulation in lysosomes.
This adversity has hampered the clinical development of PAβN (Watkins et al., 2003).
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Figure 8 Sequence of events describing PQQ4Rmechanism of action. PQQ4R mode of action involves
efflux pump inhibition, membrane permeabilization, disruption of membrane potential, and ATP deple-
tion. PQQ4R act as efflux inhibitor at low concentrations (80 µM) by interference with energy required for
efflux due to its interference with inner membrane potential. At sub-inhibitory concentrations (160 µM
and 320 µM), PQQ4R destabilizes E. colimembrane functions in a non-permanent manner as suggested
by the reduction of ATP levels, depolarization of membrane potential and increased membrane permeabi-
lization; at the MBC (640 µM), membrane permeabilization increases and ATP is lost.
The intriguing activity of PQQ4R may be used as a starting point for the much-needed
medicinal chemistry approaches to identify potent RND efflux pumps inhibitors endowed
of a suitable safety profile.
In conclusion, PQQ4R is an excellent hit candidate to be studied in depth to find
new RND efflux pumps inhibitors of Gram-negative bacteria that act by interfering
with the PMF. It shows a broad usefulness as efflux pump inhibitor and, due to its
membrane permeabilizing properties, can be used in combination therapies to assist
other molecules to enter the bacterial cell (Lamers, Cavallari & Burrows, 2013; Herbel &
Wink, 2016). Moreover, this compound complies with the conditions of Farha et al.’s
et al., (2013) hypothesis that presented an alternative approach to tackle pathogens by
using chemical combinations targeting the PMF. The authors showed that combinations
between dissipaters of membrane potential with dissipaters of the transmembrane proton
gradient are highly synergistic against methicillin-resistant S. aureus. This combination
will allow reducing each compound individual dose and consequently, their toxicity
(Farha et al., 2013). Since drug resistance mediated by efflux pumps depend largely on
the PMF, dissipaters of the PMF as PQQ4R could be regarded as putative adjuvants of
the conventional therapy against bacterial pathogens. Nevertheless, due to the similarities
between the bacterial and the mitochondrial electron transport chain, the effect of PQQ4R
on the latter will need to be evaluated in the future. Medicinal chemistry studies can now
help to improve PQQ4R scaffold to potentiate its permeabilizing and efflux inhibitory
properties and reduce its toxicity towards human cells, contributing for the development
of new drugs with potential for the clinical usage as adjuvants of the therapy against drug
resistant bacterial pathogens.
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